CVS Removes Xtandi From Its Formulary List – They Will Not Pay!

CVS Health, a major retail pharmaceutical insurer and supplier has raised some consternation and concerns and it should also raise yours. Last Tuesday, CVS rolled out their 2017 formulary list that left off the some of the world’s top-selling drugs including a vital castrate resistant prostate cancer drug. The pharmacy benefits manager removed from their [...]

Hormone Therapy (ADT) for Prostate Cancer Patients Might Provide Us Another Long Term Gift – Alzheimer’s Disease

Hormone therapy (ADT) is notorious for providing us with side effects. Some of these side effects are best described as ones that deteriorate our general quality of life. For example the most common one we all are familiar with is, of course, hot flashes. You could also add erectile dysfunction as well as loss of [...]

Pamorelin (Trelstar) Now Available in the Philippines

Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]

ASCO Releases A Statement of Principles Balancing Patient Access to Opioids with Curbing Drug Abuse

The American Association of Clinical Oncology (ASCO) released a very important new policy statement that details their position surrounding the prescribing of  opioids to cancer patients. This issue has taken the forefront of controversy as our society increasingly becomes concerned about the overuse of prescription opioids, sometimes leaving out the very specific needs of cancer [...]

Go to Top